Dr. Lal PathLabs has launched India’s first dedicated Complement Testing Laboratory, strengthening its leadership in autoimmune diagnostics. The new facility brings globally benchmarked complement assays—many introduced in India for the first time—helping doctors diagnose autoimmune, kidney-related, and recurrent infection conditions earlier and more accurately.

Complement testing is crucial as autoimmune and inflammatory diseases often show vague symptoms like fever, fatigue, and joint pain, leading to delayed diagnosis. The complement system, made up of key immune proteins such as C3, C4, and C5, can malfunction in multiple ways—becoming weak or overactive—causing repeated infections or diseases like lupus, C3 glomerulopathy, atypical HUS, vasculitis, rheumatoid arthritis, and transplant rejection.

The new lab offers advanced functional and antibody-based tests including C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional assays. According to Dr. Vandana Lal, these tests bridge a critical gap between research and routine medical care in India.

CEO Shankha Banerjee added that the platform will enable faster diagnosis, better treatment decisions, and improved outcomes for patients. The facility is equipped with modern immunoturbidimetric and ELISA platforms and adheres to CAP and NABL standards, ensuring high accuracy and reliability.

Early complement testing will help patients achieve quicker diagnosis, reduce healthcare costs, and improve long-term disease management.